Case Report Double primary germ cell tumor in a 45 year old woman: one case report and literature review

Fan Yang, Lin Kang, Huanfen Zhao

The Department of Pathology, Hebei General Hospital, Heping Xi Road, Shijiazhuang 050000, Hebei Province, China

Received May 13, 2021; Accepted August 23, 2021; Epub November 15, 2021; Published November 30, 2021

Abstract: We report a rare case of double primary germ cell tumor: right ovarian yolk sac tumor and left ovarian dysgerminoma. A 45 year-old woman was admitted to our hospital due to irregular bleeding for 2 days and extended menstrual period. Right ovarian mass was discovered on transvaginal ultrasound. The pathology results revealed that right ovarian yolk sac tumor and left ovarian dysgerminoma. Total abdominal hysterectomy with bilateral salpingo-oophorectomy with debulking with pelvic lymphadenectomy was performed. The patient underwent adjuvant chemotherapy with BEP six courses in four months and AFP dropped from 8490 ng/ml to nearly 10 ng/ml. Conclusion: Total abdominal hysterectomy with bilateral salpingo-oophorectomy followed by combination chemotherapy must be the treatment of first choice of germ cell tumor.

Keywords: Malignant germ cell tumor, double primary tumor, dysgerminoma, yolk sac tumor

Introduction

Malignant germ cell tumors are less than 5% of all ovarian neoplasms. Dysgerminoma (80%), yolk sac tumor (70%), and immature teratoma (53%) are the most common forms of malignant germ cell tumor [1]. Tumor markers such as AFP (alpha fetoprotein), hCG, and LDH are of great use in the diagnosis, prognosis, and follow-up of the disease. We report a rare case of double primary germ cell tumor: right ovarian yolk sac tumor and left ovarian dysgerminoma. We discuss the histopathological features, therapy and prognosis.

Methods and materials

Patient and sample

Germ cell tumors occurred in both sides of ovary in this case, which was extracted from the Department of Gynecology and Pathology, Hebei General Hospital. Formalin-fixed paraffin-embedded tissues were reprocessed for hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC) staining.

Immunohistochemistry

Immunohistochemical staining was performed on paraffin-embedded sections using a panel of antibodies: CD117 (SP26, Roche, China), OCT3/4 (ZM-0233, ZSGB-Bio, China), PLAP (ZA-0513, ZSGB-Bio, China), vsimentin (AR0234, Talent Biomedical, China), VSMentin (AR0234, Talent Biomedical, China), CKpan (ZM-0069, ZSGB-Bio, China), AFP (AP0008, Talent Biomedical, China), CD30 (ZM-0043, ZSGB-Bio, China), CK7 (AM0098, Talent Biomedical, China), Inhibin- α (ZM-0460, ZSGB-Bio, China), ER (1D5, Dako, CA) and HCG- β (ZM-0134, ZSGB-Bio, China). The sections were pretreated, following the manufacturer's instructions. Positive and negative controls were run concurrently for the staining of all immunomarkers.

Case report

A 45 year old woman, gravida 1 para 1, was admitted to our hospital owing to irregular bleeding for 2 days. History of the patient revealed that her menstrual cycle was regular until 8 months ago. Meanwhile, her menstrual period extended from 6-7 days to more than 20 days.



Figure 1. Photomicrograph showing right ovarian yolk sac tumor. H&E 200 ×.

She had a blood transfusion because of anemia at a local clinic. Ovarian mass was dis covered on transvaginal ultrasound in our hospital, which showed a $3.9 \text{ cm} \times 4.1 \text{ cm} \times 3.2 \text{ cm}$ mass with low echogenicity, many liquid dark areas (internal) and short rod blood flow signal, in the right adnexal area. The left ovary was about 2.7 cm \times 1.5 cm, in which there was many high echogenicity spots. The initial serum AFP level (8490 ng/ml) was much higher than normal.

Exploratory laparotomy was carried out on day 3 of her admission; an approximately 4.8 cm × 3.5 cm × 3.2 cm mass with a smooth surface was seen in the right ovary. The tumor was well-circumscribed with a gray-yellow brittle cut surface. Intraoperative examination of a frozen specimen revealed a malignant tumor. Considering where fertility preservation was not a concern, total abdominal hysterectomy with bilateral salpingo-oophorectomy with debulking with pelvic lymphadenectomy was performed. The removed uterus measured 7.0 cm × 6.0 cm × 3.0 cm. The thickness of the endometrium was 0.1 cm and the total myometrial thickness was 3.0 cm. The appearance of the cervix was normal, with length 4 cm and diameter of 4 cm. The uterine serosa, bilateral infundibulopevic ligament and fallopian tubes, left ovary, and omentum had no unusual gross features.

The pathology result revealed a right ovarian yolk sac tumor (**Figure 1**). It showed microcystic and reticular structures, which consisted of primitive cells, with loose and myxoid stroma. The tumor cells expressed CK-pan, AFP, CD117 and PLAP, but were negative for vimentin, CD30, OCT3/4, inhibin- α , HCG- β , CK7, ER, and PR (**Figure 2**). Surgical staging was Ib.

However, microscopic examination showed left ovarian dysgerminoma (**Figure 3**). It consisted of sheets of polygonal cells with abundant granular eosinophilic or clear cytoplasm and distinct cell membranes. The tumor cells had middle-sized nuclei with vesicular chromatin and prominent nucleoli. There were fibrous septa, which consisted

of lymphocytes (mostly T-cells) and epithelioid histiocytes, intersecting the tumor. Lymphocytes and epithelioid histiocytes were also sprinkled among the tumor cells. The tumor cells were positive for CK pan, vimentin, PLAP, CD117 and OCT3/4, while not expressed AFP, CD30, inhibin- α , HCG- β , CK7, ER and PR (**Figure 4**). Surgical stage was lb.

The patient underwent adjuvant chemotherapy with BEP (BLM; Etoposide VP-16; DDP) six cycles in four months. Her tumor marker of AFP was dropped from 8490 ng/ml to nearly 10 ng/ ml (**Figure 5**). During the sixth admission, she was critically ill for myelosuppression. After the treatment of leukopenia, she was better and discharged from hospital. She had survived with no evidence of disease on one year follow up.

Discussion

Malignant germ cell tumor accounts for less than 5% of all ovarian neoplasms. The incidence is 8-19% in Asia [2]. World Health Organization classified malignant germ cell tumors such as dysgerminoma, yolk sac tumor, and immature teratoma, non-gestational choriocarcinoma, embryonal carcinoma, and mixed germ cell tumor [3]. Malignant mixed germ cell tumor consists of two or more malignant germ cell components, which is quite rare but much more aggressive [4]. The most common combination reported is dysgerminoma and yolk sac tumor [5]. However, we report this case of double primary germ cell tumor. We could not find any evidence of mixed germ cell component on histopathology in either ovary.

Ovarian germ cell tumors typically occur in adolescent girls and young women [6]. Most common presenting symptoms in such patients are





Figure 3. Photomicrograph showing left ovarian dysgerminoma. H&E 200 ×.

painful abdomen, abdominal distention, or a mass in abdomen with or without irregular bleeding. Conservation of reproductive potential is of great importance as most of the patients are very young. Since these tumors are mostly unilateral and highly sensitive to chemotherapy, conservative, fertility-sparing surgery is appropriate as long as chemotherapeutic agents are given, with the addition of careful staging [7, 8]. Since fertility preservation was not required in this case, total abdominal hysterectomy with bilateral

salpingo-oophorectomy with debulking with pelvic lymphadenectomy was performed, followed by postoperative chemotherapy. Combination chemotherapy using BEP was given for 6 cycles.





Figure 5. Changes in AFP during six periods chemotherapy.

Combination chemotherapy after surgery has greatly improved the survival rate. BEP regimen is the first-line chemotherapy for malignant germ cell tumors of ovary [9]. The tumor markers that contribute to diagnosis, prognosis, and assessing therapeutic response, are β -hCG, AFP and LDH. AFP>10,000 ng/ml or β -hCG levels >50,000 mIU/ml at initial diagnosis indicate poor prognosis, with a survival rate of 50% in 5-year

[10]. After 6 cycles of chemotherapy, our patient's AFP was basically stable (nearly 10 ng/ml) with no evidence of recurrence.

In conclusion, we report one case of double primary germ cell tumor. Germ cell tumor is highly aggressive and often results in poor prognosis. Total abdominal hysterectomy with bilateral salpingo-oophorectomy followed by combination chemotherapy must be the treatment of first choice.

Acknowledgements

The present study was supported by the Research Fund of Hebei Science Foundation for young scholars (Grant No. H2017307005).

Disclosure of conflict of interest

None.

Address correspondence to: Huanfen Zhao, The Department of Pathology, Hebei General Hospital, No. 348 Heping Xi Road, Shijiazhuang 050000, Hebei Province, China. Tel: +86-13171800177; E-mail: hbghblkzhf@163.com

References

- Gershenson DM, Del Junco G, Copeland LJ and Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64: 200-6.
- [2] Lim FK, Chanrachakul B, Chong SM and Ratnam SS. Malignant ovarian germ cell tumors: experience in the national university hospital of Singapore. Ann Acad Med Singap 1998; 27: 657-61.

- Koshy M, Vijayananthan A and Vadiveloo V. Malignant ovarian mixed germ cell tumor: a rare combination. Biomed Imaging Interv J 2005; 1: e10.
- [4] Munemane A and Munemane M. Malignant mixed germ cell tumors of the ovary. A report of 2 cases. Int J Med Sci Public Health 2014; 3: 105-7.
- [5] Tiwary B, Sinha HH and Pandey VK. Malignant mixed germ cell tumor of ovary: a rare case report. Int J Reprod Contracept Obstet Gynecol 2015; 4: 511-3.
- [6] Bhurgri Y, Shaheen Y, Kayani N, Nazir K, Ahmed R, Usman A, Bashir I, Setna F, Bhurgri A, Hasan SH and Zaidi SM. Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev 2011; 12: 1567-71.
- [7] Gershensom DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol 2012; 55: 65-74.
- [8] Nishio S, Ushijima K, Fukui A, Fujiyoshi N, Kawano K, Komai K, Ota S, Fujiyoshi K and Kamura T. Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary. J Obstet Gynaecol Res 2006; 32: 416-21.
- [9] Zhao T, Liu Y, Wang X, Zhang H and Lu Y. The role of staging surgery in the treatment of apparent early-stage malignant ovarian germ cell tumors. Aust N Z J Obstet Gynaecol 2016; 56: 398-402.
- [10] Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ and Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-41.